From the Department of Bizarre Anomalies: Microsoft has suppressed an unexplained anomaly on its network that was routing traffic destined to example.com—a domain reserved for testing purposes—to a ...

KILLEEN— After more than two decades in uniform, U.S. Army Master Sgt. Fabian Balarezo is living proof that personal growth doesn’t end with rank, and that education can be a bridge between military ...

The pharmaceutical industry says a popular class of targeted cancer therapies could one day replace chemotherapy and its potential for harsh side effects. There is still more work to be done to refine ...

EBC-129 has been granted FDA fast track designation for the treatment of pancreatic ductal adenocarcinoma, paving the way for development of this antibody-drug conjugate. EBC-129, a novel ADC for the ...

Antibody-drug conjugates (ADCs) are a growing class of biotherapeutics that have transformed targeted therapy, especially in oncology. By making use of monoclonal antibodies’ specificity to deliver ...

In the chemical world, the tiny hyphen in antibody-drug conjugates—or ADCs, as they’re commonly known—does a lot more work than the perfunctory punctuation suggests. That hyphen stands for the ...

PRINCETON, N.J.--(BUSINESS WIRE)--NJ Bio, Inc. and Charles River Laboratories, Inc. have announced a strategic alliance to offer complementary services to clients including early development and ...

"These samples are the reason why our mission was flown." When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Breaking space news, the latest updates ...

Despite some positive trials with new drugs (including immunotherapy) for recurrent cervical cancer, the prognosis for this disease remains poor and additional treatment options are needed. Tisotumab ...

Ahead of the November presidential election, just 19% of Americans say democracy in the United States is a good example for other countries to follow, according to a Pew Research Center survey ...

In the second setback for the HER3 field in days, the FDA has rejected Daiichi Sankyo’s Merck & Co.-partnered antibody-drug conjugate (ADC) patritumab deruxtecan. The drug, also known as HER3-DXd, was ...